Assessment of microbial landscape and colon cytoprotection indices in patients with chronic constipations

Authors

  • Yu.M. Stepanov State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine
  • O.M. Vlasova State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine
  • I.A. Klenina State Institution “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.1.2020.199142

Keywords:

colon cytoprotection, intestinal microflora, short-chain fatty acids

Abstract

Background. The article considers the problem of chronic constipations. The results of our own studies have been shown to determine the content of short-chain fatty acids (SCFA) and the status of microbiocenosis in patients with chronic constipations before and on the background of EasyDo treatment. Materials and methods. The study involved 10 patients aged 18 to 65 years with an average duration of chronic constipation of 10 years. Patients took the combination laxative EasyDo 3 capsules a day. In order to assess the level of SCFA and the microbial landscape in patients (6 women, 4 men), a stool analysis was performed twice: before EasyDo was administered and 2 weeks after treatment. SCFA content was determined by means of a chromatographic method using hardware and software system based on the Chromateс Crystal 5000 gas chromograph. Results. A significant increase in the content of SCFA and a decrease in lactobacilli before treatment were found. After treatment, the content of acetic acid decreased significantly — by 3.9 times, to an average value of (0.011 ± 0.005) µl/ml (p < 0.05). The content of butyric acid in 90 % of patients increased significantly and was at the level of 0.018–0.131 µl/ml compared to the controls, the average value was (0.0499 ± 0.0040) µl/ml, which was significantly higher than the control values (p < 0.001). After treatment, there was an increase in the content of butyric acid to (0.061 ± 0.003) µl/ml (p < 0.05). After taking EasyDo, 60 % of patients had an improvement in the composition of the gut microbiota, a significant increase in the content of microorganisms of the Lactobacillus genus (105 CFU/g of feces); indicators of the content of other microorganisms were in the range of control va­lues. Conclusions. There was a significant increase in SCFA content in feces of patients with chronic constipations at the beginning of the observation. Treatment with the combination drug EasyDo led to a significant increase in the content of butyric acid in feces (p < 0.05), which has a positive prognostic value and indicates the activation of protective, detoxification and cytoprotective effects.

Downloads

Download data is not yet available.

References

Stepanov YM, Budzak IY, Klenina IA. Short-chain fatty acids: the role in the development of irritable bowel syndrome. Gastroenterology. 2019;1:49–53. doi:10.22141/2308-2097.53.1.2019.163458. (in Ukrainian).

Stepanov YM, Vlasova OM. The new possibilities for the treatment of patients with chronic constipation. Modern gastroenterology. 2019;1:45–50. doi:10.30978/MG-2019-1-45.

Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012;46 Suppl:S52–S55. doi:10.1097/MCG.0b013e318264e918.

Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106(2):329–336. doi:10.1038/ajg.2010.438.

de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients. 2018;11(1):51. doi:10.3390/nu11010051.

Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?. BMC Gastroenterol. 2016;16(1):51. doi:10.1186/s12876-016-0446-z.

Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe?. Int J Inflam. 2012;2012:151085. doi:10.1155/2012/151085.

Zhao G, Nyman M, Jönsson JA. Rapid determination of short-chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extraction and direct-injection gas chromatography. Biomed Chromatogr. 2006;20(8):674–682. doi:10.1002/bmc.580.

Hurst NR, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. 2014;26(11):1586–1596. doi:10.1111/nmo.12425.

Kimura I. Host Energy Regulation via SCFAs Receptors, as Dietary Nutrition Sensors, by Gut Microbiota. Yakugaku Zasshi. 2014;134(10):1037–1042. doi:10.1248/yakushi.14-00169. (in Japanese).

Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–148. doi:10.1016/j.jcmgh.2018.04.003.

Natarajan N, Pluznick JL. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol. 2014;307(11):C979–C985. doi:10.1152/ajpcell.00228.2014.

O'Malley D. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome. Exp Physiol. 2019;104(1):3–10. doi:10.1113/EP087443.

Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?. BMC Gastroenterol. 2016;16(1):51. doi:10.1186/s12876-016-0446-z.

Rau M, Rehman A, Dittrich M, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018;6(10):1496–1507. doi:10.1177/2050640618804444.

Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176. doi:10.1136/gutjnl-2012-302167.

Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42(5):491–503. doi:10.1111/apt.13283.

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119. doi:10.1016/B978-0-12-800100-4.00003-9.

Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–371. doi:10.2337/db11-1019.

Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81(3):1031–1064. doi:10.1152/physrev.2001.81.3.1031.

Verdú EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182–190. doi:10.1136/gut.2005.066100.

Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–876. doi:10.3390/nu3100858.

Downloads

Published

2021-09-06

How to Cite

Stepanov, Y., Vlasova, O., & Klenina, I. (2021). Assessment of microbial landscape and colon cytoprotection indices in patients with chronic constipations. GASTROENTEROLOGY, 54(1), 51–55. https://doi.org/10.22141/2308-2097.54.1.2020.199142

Issue

Vol. 54 No. 1 (2020)

Section

Original Researches

License

Copyright (c) 2020 Yu.M. Stepanov, O.M. Vlasova, I.A. Klenina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>